Ocular and Systemic Vascular Adverse Events Following Intravitreal Bevacizumab Injection

Research Article

J Ophthalmol & Vis Sci. 2016; 1(1): 1004.

Ocular and Systemic Vascular Adverse Events Following Intravitreal Bevacizumab Injection

Azmeh AM*

Department of Ophthalmology, Damascus University, Syria

*Corresponding author: M Arwa Azmeh, Department of Ophthalmology, Damascus University, Al Mouassat University Hospital, Damascus, Syria

Received: April 05, 2016; Accepted: April 26, 2016; Published: April 29, 2016

Abstract

During the last decade intravitreal bevacizumab has been widely used for controlling age related macular degeneration and retinal vascular disease. Since then, many reports were published reporting nonvascular ocular complications post bevacizumab injection with fewer reports about vascular ocular and systemic complications. The aim of this article is to review vascular complications, both ocular and systemic which should be considered when selecting this treatment modality, in order to reduce the rare chance of devastating events which can sometimes lead to blindness and even mortality. Ophthalmologists need to consider side effects of bevacizumab on systemic, retrobulbar and ocular circulation whenever visual loss is not attributable to progression of retinal or choroidal disease. Furthermore, ophthalmologist should be aware of possible systemic vascular complications involving the cardiovascular system, central nervous system, gastrointestinal tract, kidneys and lungs.

Keywords: Intravitreal bevacizumab; Ocular adverse events; Vascular adverse events; Systemic adverse events

Abbreviations

AMD: Age Related Macular Degeneration; DR: Diabetic Retinopathy; RVO: Retinal Vein Occlusion; CRVO: Central Retinal Vein Occlusion; BRVO: Branch Retinal Vein Occlusion; OIS: Ocular Ischemic Syndrome; ATE: Arterial Thromboembolic Events; VEGF: Vascular Endothelial Growth Factor; SAEs: Serious Adverse Events; CVA: Cerebrovascular Accident; DME: Diabetic Macular Edema; CDI: Color Doppler Imaging; PSV: Peak Systolic Velocity; EDV: End-Diastolic Velocity; PCA: Posterior Ciliary Arteries; BFV: Blood Flow Velocity; OA: Ophthalmic Artery; CRA: Central Retinal Artery; RI: Resistant Index; CRAO: Central Retinal Artery Occlusion; BRAO: Branch Retinal Artery Occlusion; NAION: Nonarteritic Anterior Ischemic Optic Neuropathy; LP: Light Perception; NLP: No Light Perception; IOP: Intraocular Pressure; RE: Right Eye; LE: Left Eye; MI: Myocardial Infarction

Terminology

Half-life time: How long it takes for the body to get rid of half of the dose of medicine.

Introduction

Intravitreal injection of anti-Vascular Endothelial Growth Factor (VEGF), became the standard of care in many common retinal diseases including Age related Macular Degeneration (AMD) [1] and retinal vascular diseases such as Diabetic Retinopathy (DR) [2], Retinal Vein Occlusions (RVO) and Ocular Ischemic Syndrome (OIS) [3]. Due to short intravitreal half-life of bevacizumab [4], repeated injections are needed to inhibit angiogenesis and to maintain control of activity of sub retinal new vessels in AMD as well as leaking from retinal capillaries in retinal vascular diseases [5-8]. Few reports were published describing devastating ocular and systemic vascular complications post intravitreal bevacizumab injection [9-24].

The aim of this article is to review vascular complications, both ocular and systemic which should be considered when selecting this treatment modality, in order to reduce the rare chance of devastating events which can sometimes lead to blindness and even mortality.

Methods

The MEDLINE database was searched for the past 10 years using the keyword “intravitreal bevacizumab”. 2958 results were obtained. The articles list was analyzed and 339 articles were chosen, which were thought to be related to this review about ocular and systemic intravitreal bevacizumab side effects. After reviewing abstracts of the 339 chosen articles, 102 of them were found to be directly related to the subject. Full texts of the latter articles were obtained and used in this review.

Results and Discussion

Intravenous bevacizumab is widely used in treatment of many solid cancers [9,25]. Several adverse events have been reported with its intravenous administration including Arterial Thromboembolic Events (ATE), myocardial infarction, stroke, hypertension, gastrointestinal perforations, and kidney disease [10,26-31]. Recently, these observations have been extended to patients receiving intravitreal VEGF inhibitors [32].

Anti-VEGF agents became one of the main treatments of AMD and retinal vascular diseases [1-3]. Due to high cost of FDA approved anti-VEGFs, off-label intravitreal bevacizumab is often used in practice all over the world as it is very low in cost and as effective as other approved anti-VEGFs [5-7].

The incidence of serious ocular and systemic adverse events was approximately below 1 per 100 injections for intravitreal bevacizumab, intravitreal ranibizumab, and intravitreal pegaptanib. Most mild ocular adverse events were below 5 per 100 injections [33].

Ocular and systemic nonvascular bevacizumab adverse events

Adverse nonvascular ocular events following intravitreal bevacizumab [34] included: Endophthalmitis [35-41], non infectious intraocular inflammation [26,42-44], rhegmatogenous retinal detachment [26,45]. Tractional retinal detachment [46], macular hole [47], intraocular pressure elevation [48-52], subconjunctival hemorrhage [7], massive subretinal hemorrhage [12,53], retinal pigment epithelium tear [54-56], intravitreal foreign body [57], Lens trauma [58,59], corneal complications [60-62], wound leak [63].

Meyer CH et al. [20] reported 2 cases of transient structured visual hallucinations in 2 patients with exudative AMD, one day and three days after intravitreal bevacizumab injection. Both patients experienced structured hallucinations including trees, faces, and water for approximately 15 to 30 minutes. Authors hypothesized that reduced retinal edema and realignment of the photoreceptors may cause this phenomenon and trigger hallucinatory episodes.

Ocular and Systemic bevacizumab vascular adverse events

As the commonly used intravitreal anti-VEGF agents were found to transit rapidly into the bloodstream after administration [64,65], concern about their systemic side effects was raised by retina specialists [64,66]. It was reported that small doses used for eye disease seem to be safe, but these agents are very potent, and there are several lines of evidence that imply that these small doses could potentially have a systemic effect [66,67].

Since treatment trials are designed primarily to assess the prevention of vision loss caused by ocular conditions, they are inadequate for detecting rare, but potentially serious, systemic side effects [64,68]. A number of clinical trials have demonstrated an association between anti-VEGF therapies and increased cardiovascular events [32]. There is an increased risk of arterial thromboembolism, but not of venous thromboembolism, in patients with metastatic carcinoma treated with chemotherapy and systemic bevacizumab. Patients with cancer are at increased risk of a thrombotic event, which rises further when bevacizumab is administered [10,13].

In a retrospective study of 1173 patients receiving intravitreal bevacizumab injections [69], the reported systemic events included acute blood pressure elevations (0.59%), cerebrovascular accidents (0.5%), myocardial infarctions (0.4%), iliac artery aneurysms (0.17%), and death (0.42%) [69]. WY Ng et al. [23] analyzed 1011 individuals treated with intravitreal bevacizumab for AMD and found that the incidence rate of myocardial infarction, stroke and death in their cohort of AMD patients was low and not significantly higher than the age adjusted incidence rate of these events in Singapore population.

CATT trial found an increased risk of systemic Serious Adverse Events (SAEs) in the bevacizumab treated patients versus the ranibizumab treated group [70]: all-cause mortality was 2.8% in ranibizumab versus 2.9% in bevacizumab (P = 1.00), arteriothrombotic events: 2.2% in ranibizumab versus 1.7% in bevacizumab (P = 0.68), Stroke: 1.2% in ranibizumab versus 1.2% in bevacizumab (P = 1.00).

Although a meta- analysis published 2 years ago of nine AMD trials did not confirm increased incidence in SAEs following bevacizumab injection [71], Avery RL performed a more current update of this analysis and confirmed the original finding of a significant risk with bevacizumab [67]. This finding is consistent with the pharmacokinetic data that show much higher systemic exposure from bevacizumab than ranibizumab, as well as a much more pronounced reduction in plasma and serum VEGF with bevacizumab [65,67,72-74].

Two years data from the IVAN trial [75], demonstrated a statistically significant increase in risk of systemic adverse events (including cardiovascular) with bevacizumab compared with ranibizumab. These findings may, in part, be explained by the systemic absorption of these agents, determined by the presence of an Fc fragment on bevacizumab and aflibercept, facilitating recycling and systemic absorption, whereas ranibizumab lacks an Fc receptor and accordingly has a shorter systemic half-life. Avery et al. have previously demonstrated marked reductions in plasma VEGF levels following bevacizumab and aflibercept injections, but with minimal reduction following ranibizumab injections, with corresponding systemic absorptions 70 fold higher for bevacizumab and 13 fold higher for aflibercept compared with ranibizumab [65]. Taken together, these data suggest that systemic absorption of intravitreal VEGF inhibitors may determine their adverse cardiovascular effects, particularly in those patients at high baseline risk [75].

Given the higher baseline risk for ATEs in patients with diabetes [32,76], most Diabetic Macular Edema (DME) trials have excluded patients with recent Cerebrovascular Accidents (CVAs) or Myocardial Infarctions (MIs). Several recent meta-analyses of patients treated for DME have not shown a statistically significant increased risk of ATEs or death across all treatment regimens, but one did raise concerns about a dose-dependent increased risk of death in a subset of patients [67,77-79].

Other reported bevacizumab vascular systemic side effects included rupture of abdominal aortic aneurysm [80].

Pathogenesis of bevacizumab vascular adverse events

Several studies showed reduced systemic VEGF levels after intravitreal anti-VEGF injections. Elevated levels of anti-VEGF drugs in the bloodstream were correlated with the decreased VEGF levels [65,67,72-74]. Systemic and ocular side effects of intravitreal anti-VEGF injections are mainly vascular, related to the inhibition of Vascular Endothelial Growth Factor (VEGF) [10,14,81,82]. Concerns about its side-effects on the retrobulbar and systemic circulatory system were raised [10,14].

Mete et al. [83] studied the effect of intravitreal bevacizumab in AMD on retrobulbar blood flow using Color Doppler Imaging (CDI) at 1 day post injection. They found that Peak Systolic Velocity (PSV) and End-Diastolic Velocity (EDV) of Posterior Ciliary Arteries (PCA) were significantly decreased, whereas Blood Flow Velocity (BFV) of Ophthalmic Artery (OA) and Central Retinal Artery (CRA), as well as Resistant Index (RI) of OA, PCA and CRA did not show any statistically significant difference at 1 day post injection.

Bonnin et al. [84] also analyzed the effect of intravitreal bevacizumab in AMD patients on retrobulbar blood flow, at 4 weeks post injection and found a decrease in mean BFV of CRA, PCA and OA.

Tolku et al. [85] found a decrease in BFV of CRA and PCA and increased RI of CRA and PCA with no significant change in the BFV of OA at the end of 1st week after intravitreal bevacizumab for AMD. These parameters returned to preoperative values at the end of 1st month post injection.

In spite of some differences between the 3 previous studies [83- 85] regarding effect of intravitreal bevacizumab in AMD patients on retrobulbar blood flow in PCA, CRA and OA, all of them confirmed the effect of intravitreal bevacizumab on decreasing the blood flow in PCA in the early post injection period starting from 1 day till 4 weeks post injection. These changes in choroidal circulation may be attributed to different factors including:

Download PDF

Citation: Azmeh AM. Ocular and Systemic Vascular Adverse Events Following Intravitreal Bevacizumab Injection. J Ophthalmol & Vis Sci. 2016; 1(1): 1004.

Home
Journal Scope
Online First
Current Issue
Editorial Board
Instruction for Authors
Submit Your Article
Contact Us